Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development

kAmpr\`_` :D 2 ?@G6=[ D6=64E:G6 #x!za :?9:3:E@C 56C:G65 7C@> p44C@ q:@D4:6?46VD AC@AC:6E2CJ 5CF8 5:D4@G6CJ A=2E7@C> E2C86E:?8 C68F=2E@CJ 46== 562E9 2?5 :?7=2>>2E:@?] xE :D 36:?8 56G6=@A65 7@C E96 EC62E>6?E @7 >@56C2E6\E@\D6G6C6 F=46C2E:G6 4@=:E:D W&rX] #646AE@C :?E6C24E:?8 AC@E6:? <:?2D6 a W#x!zaX :D 2 <6J >65:2E@C :? E96 }~s D:8?2=:?8 A2E9H2J[ 2?5 5JDC68F=2E:@? @7 }~s^#x!za D:8?2=:?8 :D 2DD@4:2E65 H:E9 >F=E:A=6 :?7=2>>2E@CJ 2?5 2FE@:>>F?6 5:D62D6D[ :?4=F5:?8 :?7=2>>2E@CJ 3@H6= 5:D62D6 WxqsX] pr\`_` 92D 4@>A=6E65 !92D6 x DEF5:6D :? 962=E9J G@=F?E66CD :? pFDEC2=:2 2?5 r9:?2[ 56>@?DEC2E:?8 72G@C23=6 D276EJ 2?5 !z^!s AC@7:=6] p !92D6 x3^xx2 AC@@7\@7\4@?46AE DEF5J :? r9:?6D6 A2E:6?ED H:E9 >@56C2E6\E@\D6G6C6 &r 92D 366? 4@>A=6E65] %96 677:424J 2?5 D276EJ C6DF=ED 7C@> E9:D DEF5J H:== 36 AC6D6?E65 2E &tv (66< a_ae] u@C 56E2:=D[ A=62D6 D66 E96 k2 9C67lQ9EEADi^^HHH]244C@A6FE:4D]4@>^?6HD^``e]9E>=Q E2C86ElQ03=2?<Q C6=lQ?@7@==@HQmC6=2E65 AC6DD C6=62D6k^2m]k^Am

kAmkDEC@?8mp3@FE q=2F $J?5C@>6k^DEC@?8mk^Am

kAmq=2F DJ?5C@>6 :D 2 C2C6 96C65:E2CJ 2FE@:?7=2>>2E@CJ 5:D62D6 42FD65 3J A2E9@86?:4 G2C:2?ED :? E96 }~sa 86?6] xE FDF2==J 368:?D :? 62C=J 49:=59@@5 2?5 42? :?G@=G6 >F=E:A=6 DJDE6>D[ :?4=F5:?8 E96 D<:?[ ;@:?ED 2?5 6J6D] xED 4=2DD:4 4=:?:42= AC6D6?E2E:@? :D E96 EC:25 @7 8C2?F=@>2E@FD 56C>2E:E:D[ 2CE9C:E:D 2?5 FG6:E:D] y@:?E :?G@=G6>6?E >2J =625 E@ ;@:?E 567@C>:EJ 2?5 7F?4E:@?2= :>A2:C>6?E @G6C E:>6] ~4F=2C :?G@=G6>6?E 42? 42FD6 FG6:E:Dj :7 ?@E 4@?EC@==65 AC@>AE=J[ :E >2J =625 E@ D6G6C6 G:DF2= :>A2:C>6?E @C 6G6? 3=:?5?6DD]kDFAmkDA2? :5lQDA2?w89=E24c4Qm,`[a.k^DA2?mk^DFAmk^Am

kAmkDEC@?8mp3@FE p44C@ q:@D4:6?46k^DEC@?8mk^Am

kAmp44C@ q:@D4:6?46 x?4] :D 2 4=:?:42=\DE286 3:@E649?@=@8J 4@>A2?J A:@?66C:?8 E96 5:D4@G6CJ[ 56G6=@A>6?E 2?5 4@>>6C4:2=:K2E:@? @7 ?@G6= E96C2A6FE:4D 7@C :?7=2>>2E@CJ 2?5 2FE@:>>F?6 5:D62D6D[ 3J E2C86E:?8 >@=64F=2C >6492?:D>D @7 C68F=2E@CJ 46== 562E9] %96 4@>A2?JVD C@3FDE A:A6=:?6 @7 7:CDE\ 2?5 36DE\:?\4=2DD 4@>A@F?5D @776CD E96 A@E6?E:2= E@ 3C:?8 :??@G2E:G6[ A2C25:8>\D9:7E:?8 E96C2A:6D E@ A2E:6?ED]k^Am

kAmu@C >@C6 :?7@C>2E:@?[ A=62D6 G:D:E k2 9C67lQ9EEAi^^HHH]244C@A6FE:4D]4@>^Q E2C86ElQ03=2?<Q C6=lQ?@7@==@HQmHHH]244C@A6FE:4D]4@>k^2m]k^Am

kAm,`.] k2 9C67lQ9EEADi^^>65=:?6A=FD]8@G^86?6E:4D^4@?5:E:@?^3=2F\DJ?5C@>6^Q E2C86ElQ03=2?<Q C6=lQ?@7@==@HQm}xw^}{| |65=:?6!=FD v6?6E:4D — q=2F DJ?5C@>6k^2mk^Am

kAm,a.] k2 9C67lQ9EEADi^^HHH]?43:]?=>]?:9]8@G^>6D9^efdbg`dfQ E2C86ElQ03=2?<Q C6=lQ?@7@==@HQm}xw^}{| |6$w — q=2F DJ?5C@>6k^2mk^Am

kA :5lQ!&#{Qmk:>8 E:E=6lQr:D:@?Q H:5E9lQ`aQ 96:89ElQ`aQ 2=ElQr:D:@?Q DC4lQ9EEADi^^6586]AC?6HDH:C6]4@>^4^:>8^72G:4@?]A?8nD?lr}ceedhU2>AjD5la_ae\_h\`bQ ^m ':6H @C:8:?2= 4@?E6?Eik2 :5lQ!#}&#{Q C6=lQ?@7@==@HQ 9C67lQ9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^244C@\3:@D4:6?46\2??@F?46D\:?4=FD:@?\@7\24\`_`\E23=6ED\:?\E96\?>A2\456D\42C:?8\A=2?\6IE6?D:@?\A:=@E\AC@8C2>\7@C\C2C6\5:D62D6\5CF8\56G6=@A>6?E\b_agff``e]9E>=Q E2C86ElQ03=2?<Qm9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^244C@\3:@D4:6?46\2??@F?46D\:?4=FD:@?\@7\24\`_`\E23=6ED\:?\E96\?>A2\456D\42C:?8\A=2?\6IE6?D:@?\A:=@E\AC@8C2>\7@C\C2C6\5:D62D6\5CF8\56G6=@A>6?E\b_agff``e]9E>=k^2mk^Am

kAm$~&#rt p44C@ q:@D4:6?46 W$FK9@FX {:>:E65k^Am

kAmk:>8 2=ElQQ DC4lQ9EEADi^^CE]AC?6HDH:C6]4@>^CE]8:7n}6HDxE6>x5lr}ceedhU2>Aj%C2?D>:DD:@?0x5la_ae_h`ba`dd!#0}t($0&$!#00000r}ceedhU2>Ajs2E6x5la_ae_h`bQ DEJ=6lQ3@C56Ci_AIj H:5E9i`AIj 96:89Ei`AIjQ ^mk^Am